SUPN - Supernus Pharmaceuticals, Inc.
| Previous Close | 21.83 |
| Open | 21.90 |
| Bid | 21.00 x 1200 |
| Ask | 23.00 x 2200 |
| Day's Range | 21.62 - 22.10 |
| 52 Week Range | 19.35 - 49.25 |
| Volume | 411,575 |
| Avg. Volume | 652,810 |
| Market Cap | 1.158B |
| Beta (3Y Monthly) | 1.63 |
| PE Ratio (TTM) | 11.27 |
| EPS (TTM) | 1.96 |
| Earnings Date | Nov 5, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 25.67 |
- American City Business Journals
Supernus Pharmaceuticals seeks FDA approval for ADHD drug
The fate of a local company’s treatment for attention deficit hyperactivity disorder is now in regulators’ hands. Supernus Pharmaceuticals Inc. (NASDAQ: SUPN) has submitted its application to the Food and Drug Administration to take its ADHD drug to market, the company announced Monday. Supernus has put the product candidate through a handful of phase 3 clinical trials, to study its ability to reduce ADHD symptoms.
- GlobeNewswire
Supernus to Present at Two November Healthcare Conferences
ROCKVILLE, Md., Nov. 12, 2019 -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of.
- Benzinga
The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 11) ACADIA Pharmaceuticals Inc (NASDAQ: ACAD ) Agenus Inc ...
- GlobeNewswire
Supernus Submits New Drug Application for SPN-812 for the Treatment of ADHD
Supernus Pharmaceuticals, Inc. (SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for SPN-812 for the treatment of patients with attention deficit hyperactivity disorder (ADHD). SPN-812 is a well differentiated product candidate that, if approved by the FDA, can become a unique multi-symptom treatment option for many patients with ADHD. It is a non-controlled substance that is easy to use and that has shown in clinical studies a reduction in ADHD symptoms observed as early as week one and continued until the end of the studies.
- Thomson Reuters StreetEvents
Edited Transcript of SUPN earnings conference call or presentation 6-Nov-19 2:00pm GMT
Q3 2019 Supernus Pharmaceuticals Inc Earnings Call
- TheStreet.com
How to Profit From Market Overreactions
A look at Supernus Pharmaceuticals and TPI Composites provides a tutorial on reaping rewards from stocks the market suddenly hates.
- Benzinga
The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 6) Agile Therapeutics Inc (NASDAQ: AGRX )(follow-on rally ...
- Benzinga
The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 5.) Agile Therapeutics Inc (NASDAQ: AGRX ) (follow-on ...
- Zacks
Supernus Pharmaceuticals (SUPN) Q3 Earnings and Revenues Lag Estimates
Supernus (SUPN) delivered earnings and revenue surprises of -8.47% and -6.51%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Supernus Announces Third Quarter 2019 Financial Results and Topline Data from Phase III Study of SPN-810 for Treatment of Impulsive Aggression (IA) in ADHD Patients
Total revenue of $102.1 million, compared to $103.0 million in third quarter 2018Net product sales of $100.0 million, compared to $100.2 million in third quarter 2018Operating.
- Zacks
Supernus Pharmaceuticals (SUPN) Reports Next Week: Wall Street Expects Earnings Growth
Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Insider Monkey
Were Hedge Funds Right About Dumping Supernus Pharmaceuticals Inc (SUPN)?
The first quarter was a breeze as Powell pivoted, and China seemed eager to reach a deal with Trump. Both the S&P 500 and Russell 2000 delivered very strong gains as a result, with the Russell 2000, which is composed of smaller companies, outperforming the large-cap stocks slightly during the first quarter. Unfortunately sentiment shifted […]
- GlobeNewswire
Supernus to Host Third Quarter 2019 Earnings Conference Call
ROCKVILLE, Md., Oct. 24, 2019 -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of.
- Simply Wall St.
Estimating The Fair Value Of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
Does the October share price for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) reflect what it's really worth? Today...
- Simply Wall St.
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Insiders Increased Their Holdings
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
- GlobeNewswire
Supernus to Present at the 2019 Cantor Global Healthcare Conference
ROCKVILLE, Md., Sept. 25, 2019 -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment.
- GuruFocus.com
5 Health Care Stocks Gurus Are Buying
Merit Medical Systems makes the list Continue reading...
- Simply Wall St.
How Does Investing In Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Impact The Volatility Of Your Portfolio?
Anyone researching Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) might want to consider the historical volatility of...
- TheStreet.com
There's Value In These 2 Small Beaten Down Biotech Stocks
The market continues to ebb and flow with the direction of trade tensions. Yesterday, markets rallied strongly on some encouraging remarks from the Chinese delegation about the prospects for further trade talks.
- GuruFocus.com
Supernus Pharmaceuticals Inc (SUPN) President, CEO Jack A. Khattar Bought $190,008 of Shares
President, CEO of Supernus Pharmaceuticals Inc (30-Year Financial, Insider Trades) Jack A. Khattar (insider trades) bought 7,200 shares of SUPN on 08/23/2019 at an average price of $26.39 a share. Continue reading...
- GlobeNewswire
Supernus to Present at Two September Healthcare Conferences
ROCKVILLE, Md., Aug. 26, 2019 -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of.
- Thomson Reuters StreetEvents
Edited Transcript of SUPN earnings conference call or presentation 7-Aug-19 1:00pm GMT
Q2 2019 Supernus Pharmaceuticals Inc Earnings Call
- Zacks
Can Value Investors Pick Supernus Pharmaceuticals (SUPN)?
Let's see if Supernus Pharmaceuticals (SUPN) stock is a good choice for value-oriented investors right now from multiple angles.
- Simply Wall St.
These 4 Measures Indicate That Supernus Pharmaceuticals (NASDAQ:SUPN) Is Using Debt Safely
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Motley FoolSupernus Pharmaceuticals Inc (SUPN) Q2 2019 Earnings Call Transcript
SUPN earnings call for the period ending June 30, 2019.
